Navigation Links
Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop
Date:2/23/2009

receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions. Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy. Patients on oral antidiabetic medication while receiving VELCADE should check blood sugar levels frequently.

Adverse Reaction Data

Safety data from Phase II and III studies of single-agent VELCADE 1.3 mg/m2/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with previously treated multiple myeloma (N=1008, not including the Phase III, VELCADE plus DOXIL(R) [doxorubicin HCl liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma.

In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
2. Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
3. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
4. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
5. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
6. Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
7. FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
8. Inexpensive and Illegal Buttock - Boosting Injections Not Pretty
9. Radiofrequency treatment better than ethanol injection for small liver tumors
10. Bedford Laboratories(TM) to Begin Shipping Irinotecan HCl Injection
11. Cosmetic Injections A Worthwhile Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- Patients with the progressive, ... (COPD) have a new weapon to battle the disease, ... The agency approved a new treatment, an inhaled ... leading killer of Americans. COPD, which is often linked ... bronchitis and emphysema. Patients with COPD may ...
(Date:8/1/2014)... According to new market research ... North America, Europe, & ROW), by Vehicle Type ... (Gasoline & Diesel), by After-Treatment Device (DPF, DOC, ... Forecasts to 2019", defines and segments the global ... major countries in all the regions, and estimates ...
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 ... industry have benefited from innovative technologies that have ... resemble a patient's tooth color. Moreover, the burgeoning ... due to age-related tooth ailments. Due to long-term ... many elderly individuals have demanded dental fillings, veneers ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 ... Market Outlook to 2020", provides key market ... market. The report provides value, in millions ... average prices (in US dollars) within market ... Ultrasonic Generators and Argon Plasma Coagulation Generators. ...
(Date:8/1/2014)... Kathleen Doheny HealthDay Reporter ... control pills containing high doses of estrogen, along with ... cancer in women under 50, new preliminary research ... lead researcher Elisabeth Beaber, a staff scientist at the ... these formulations increase breast cancer risk while other formulations ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Treatment for People With COPD 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3
... case of virgin birth in cartilaginous fish, after busting the mystery ... had only female sharks which had no contact with a male ... at Omaha's Henry Doorly Zoo, in the US, in December 2001 ... the female sharks in the aquarium. ,Female sharks have ...
... are in favour of a ban on smoking in workplaces ... ,Some 88 percent of citizens in the European Union ... a study by the European Commission, the bloc's executive arm. ... support for anti-tobacco policies could help make European public and ...
... the concerns of developing countries like Indonesia, the Unjted Nations ... efforts would be made to ensure "fair and equitable distribution ... of a pandemic." ,At the same time the ... WHO. ,A resolution on those lines ...
... a meeting of the U.N. General Assembly to review the ... it is possible to halt and reverse the spread of ... worldwide. ,U.N. member countries last year renewed pledges ... prevention, treatment and care services by 2010. In addition, one ...
... shown that a compound extracted from a plant from the ... and block its effect on the brain. ... Drug Abuse found that upon administration of the plant extract, ... tetrahydrocannabinol (THC), an active compound in marijuana. The treatment also ...
... in Vietnam confirmed Wednesday the possibility that a resident of ... contracted the lethal H5N1 strain of the bird flu virus, ... ,A fresh outbreak of bird flu has hit five provinces ... strain after being hospitalized in serious condition. ...
Cached Medicine News:Health News:WHO Announces Deal on Sharing Bird Flu Virus 2Health News:U.N. Secretary-General Ban Renews Goal To Reverse Spread of HIV by 2015 2Health News:Compound Present in Plant may Help to Curb Craving for Cannabis 2
(Date:7/31/2014)... CHESTERBROOK, Pa. , July 31, 2014   ... a fully integrated specialty biopharmaceutical company, today announced that ... of 2014 on Thursday, August 7, 2014 before the ... will conduct a conference call that day at 8:30 ... second quarter of 2014. The presentation slides to be ...
(Date:7/31/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... of its lead molecule, Anatabine Citrate, in ... Clinical, The Translational Pharmaceutics Company, based in the ... early development programs. The Company expects to ... of the third quarter with the Medicines Healthcare products ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources Group ... market intelligence product Marketrack to now include ChinaTrack; the ... device landscape in an interactive dashboard providing detailed brand-level ... volumes at a hospital level. Other key ... Updated data feed: In addition to end-user surveys of ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... , HOPKINTON, Mass., Nov. 2 Caliper Life Sciences, Inc. ... tools, presented at a training session for reviewers from the ... of the LabChip GX platform for high throughput screening and ... accept the FDA,s invitation to present our LabChip platform to ...
... This week begins American Diabetes Month® - a ... the launch of a new campaign by the American Diabetes ... and one of its National Strategic Partners, Liberty Medical Supply, ... give diabetes patients practical tips and advice for living with ...
Cached Medicine Technology:Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration 2Educational Video Series Released for American Diabetes Month 2Educational Video Series Released for American Diabetes Month 3Educational Video Series Released for American Diabetes Month 4
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: